Identifying Biomarkers for Early Detection of Cancer in Patients With Cervical Dysplasia or Carcinoma in Situ of the Cervix
Study Details
Study Description
Brief Summary
RATIONALE: Studying the genes expressed in samples of tissue from patients with abnormal cells may help doctors identify biomarkers related to cancer.
PURPOSE: This clinical trial is identifying biomarkers for early detection of cancer in women with cervical dysplasia or carcinoma in situ of the cervix.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
OBJECTIVES:
Primary
-
To identify and catalogue genetic alterations and protein changes associated with developmental stages of cervical cancer.
-
To identify a ranked list of candidate genes that drive the transformation of premalignant lesions to tumors for further study and validation as molecular targets for novel early detection and treatment design.
Secondary
-
To complete genome scans at high density and analysis of gene and protein expression to identify recurrent genetic and protein changes in cancer.
-
To confirm changes clustered to specific chromosomal regions which harbor tumor suppressors or oncogenes.
OUTLINE: Patients undergo biopsy of cervical tissue followed by loop electrocautery excision procedure (LEEP) (removing all of the tissue surrounding and under the area biopsied). RNA, DNA, and protein is extracted from the cells to provide material for the construction of libraries for Serial Analysis of Gene Expression (SAGE analysis); for hybridization against Bacterial Artificial Chromosome Comparative Genome Hybridization arrays (BAC CGH arrays); and for analysis using protein chip arrays and proteomics. Resulting data from coded samples provide gene expression and protein profiles. The coded molecular datasets are linked, analyzed, and compared using a variety of statistical software to identify putative genes, gene alterations, and proteins of interest. Some samples may be banked for future studies.
Study Design
Outcome Measures
Primary Outcome Measures
- Identify and catalogue genetic alterations and protein changes associated with developmental stages of cervical cancer [Done at the completion of the study.]
- Identify a ranked list of candidate genes that drive the transformation of premalignant lesions to tumors for further study and validation as molecular targets for novel early detection and treatment design [Done at the completion of the study.]
- Completion of genome scans at high density and analysis of gene and protein expressions to identify recurrent genetic and protein changes in cancer [Done at the completion of the study.]
- Changes clustered to specific chromosomal regions which harbor tumor suppressors or oncogenes [Done at the completion of the study.]
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Histologically or cytologically confirmed premalignant lesion, dysplasia, or carcinoma in situ of the cervix
-
Clinically documented disease
-
Attending Vancouver General Hospital and referred to colposcopy for loop electrocautery excision procedure (LEEP)
PATIENT CHARACTERISTICS:
-
Not pregnant
-
No lack of informed consent due to language difficulty, physical and mental condition
PRIOR CONCURRENT THERAPY:
-
No prior operation for removal of the cervix
-
Concurrent therapy allowed
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- British Columbia Cancer Agency
- National Cancer Institute (NCI)
Investigators
- Study Chair: Sylvia Lam, British Columbia Cancer Agency
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CDR0000581302
- R01CA103830
- BCCR-H04-60112
- BCCR-RO4-0112